Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cellular & Molecular Immunology|November 3, 2020
Tumor-infiltrating lymphocytes in the immunotherapy eraSterre T Paijens, Annegé Vledder, Marco de Bruyn, et al.
BJC Reports|July 7, 2025
IL-6R expression is an independent prognostic factor in high-grade serous ovarian cancerAlexis M Maagdenberg, Annegé Vledder, Sterre T Paijens, et al.
The Cochrane Database of Systematic Reviews|September 11, 2018
Antigen-specific active immunotherapy for ovarian cancerSterre T Paijens, Ninke Leffers, Toos Daemen, et al.
Cancers|April 23, 2022
Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial CancerJoyce M Lubbers, Marta A Ważyńska, Nienke van Rooij, et al.
Oncoimmunology|September 14, 2020
Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcomeKim L Brunekreeft, Sterre T Paijens, Maartje C A Wouters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II TrialAnneke L Eerkens, Martha D Esajas, Koen Brummel, et al.
International Journal of Cancer|August 22, 2024
B cells critical for outcome in high grade serous ovarian carcinomaAnnegé Vledder, Sterre T Paijens, Dominik Loiero, et al.
Gynecologic Oncology|June 4, 2021
FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoringJolijn W Groeneweg, Joline F Roze, Edith D J Peters, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 7, 2020
First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced CancersFenne L Komdeur, Amrita Singh, Stephanie van de Wall, et al.
Nature Communications|September 3, 2024
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I studyAnneke L Eerkens, Koen Brummel, Annegé Vledder, et al.
Pageof 1